TJ

Timothy J. Barberich

North America, Massachusetts, United States, Cambridge

Description

Tim Barberich is the Director at Newcastle Holdings and was a Chairman and CEO of Sunovion Pharmaceuticals. Tim attended Rutgers University ...

Investor Profile

Timothy J. Barberich has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series Unknown, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Clinical Trials, Health Care.

Stage Focus

  • Series Unknown (50%)
  • Series A (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Clinical Trials
  • Health Care
  • Neuroscience
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Timothy J. Barberich frequently co-invest with?

Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2
Tekla Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
Venture Investors
North America, Wisconsin, United States, Madison
Co-Investments: 1
State of Wisconsin Investment Board
North America, Wisconsin, United States, Madison
Co-Investments: 2
GBS Ventures
Oceania, Victoria, Australia, Melbourne
Co-Investments: 2
HH
North America, Massachusetts, United States, Boston
Co-Investments: 2

What are some of recent deals done by Timothy J. Barberich?

Neurovance

Cambridge, Massachusetts, United States

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

BiotechnologyClinical TrialsHealth CareNeuroscience
Series AApr 3, 2014
Amount Raised: $6,300,000
Neurovance

Cambridge, Massachusetts, United States

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

BiotechnologyClinical TrialsHealth CareNeuroscience
Series UnknownOct 18, 2012
Amount Raised: $7,000,000